Stemcentrx

Showing 3 posts of 3 posts found.

abbvie_0

AbbVie records an estimated $4billion in impairment charges after failure of cancer drug Rova-T

January 8, 2019
Manufacturing and Production AbbVie, M&A, MA, Stemcentrx, acquisition, rova-t

US firm AbbVie has said that it will record an estimated $4 billion in impairment charges related to the abandonment …

abbvie_0

AbbVie says Stemcentrx’ lung cancer drug shows some benefits in early trials

June 6, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t

US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …

abbvie_0

AbbVie says Stemcentrx’ stem cell drug shows some benefits in early trials

June 6, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t

US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …

Latest content